Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end ...

‘When it comes back to a M&A perspective, we look for a cultural fit and the right customer base that fits in with our own,’ says Mark Lee, UK president of Fulcrum IT Partners. After acquiring ...